6th Jul 2009 07:00
Millipore and Proteome Sciences Announce Licensing Agreement
Companies to develop innovative research tools to advance the study of Alzheimer's Disease
Cobham, UK and Billerica, Ma-July 6, 2009- Proteome Sciences plc (LSE PRM) ('Proteome Sciences' or the 'Company') and Millipore Corporation (NYSE MIL) ('Millipore') today announced that they have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer's disease. Under the terms of the agreement, Millipore will develop Luminex bead-based multiplex immunoassays to measure Proteome Sciences' proprietary Alzheimer's disease biomarkers. The ability to quickly test for these biomarkers will enable researchers to develop new drugs and diagnostics to treat and monitor patients with Alzheimer's.
"We are pleased to be working with Millipore," said Proteome Sciences' CEO Christopher Pearce. "We see this as a key step in the development of clinical tests for Alzheimer's disease. These diagnostics will help scientists more precisely diagnose and monitor Alzheimer's disease in its early stages, which are critically important."
Proteome Sciences has established a strong portfolio of patent-protected blood biomarkers of Alzheimer's disease working in collaboration with the Institute of Psychiatry (IoP) at King's College, London. A number of these biomarkers have been independently identified and their relationship to Alzheimer's disease confirmed by researchers at GlaxoSmithKline.
"This collaboration will help us achieve our broader goal of advancing the study of neurobiology and neurodegenerative diseases," said Jonathan DiVincenzo, President of Millipore's Bioscience Division. "By expanding our portfolio of multiplex immunoassays targeting Alzheimer's disease biomarkers, we will complement our portfolio of products for neuroscience that includes antibodies and ELISAs, neural stem cells, specialty media, and cell-based high content analysis kits. The development of a comprehensive multiplex Alzheimer's panel will accelerate research and ultimately lead to better monitoring as a clinical tool."
Millipore will acquire the exclusive right to develop and sell Luminex bead-based panels for research related to the study of Alzheimer's disease and other cognitive function disorders. Proteome Sciences retains all rights to clinical applications of these biomarkers. Financial terms of the license agreement were not disclosed.
Alzheimer's disease - Background
5.3 million Americans have Alzheimer's disease
A suspected new case is identified every 70 seconds in the US
It is 5th leading cause of death in persons over the age of 65
Economic costs exceed $142 bn in 2005 with $112 bn in direct medical costs
10-20% of over persons over the age of 65 have mild cognitive impairment that may develop into Alzheimer's disease.
About Proteome Sciences:
Proteome Sciences is a leading biomarker CRO providing protein biomarker discovery, validation and assay development services. The Company's MS Biomarker Assay system (MBA) uses its proprietary isobaric Tandem Mass Tags (TMT®) and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed in weeks and are suitable for screening 10's to 100's of candidate biomarkers in validation studies. Assays for validated biomarkers can be rapidly developed using the same isotope dilution mass spectrometry format, or can be transferred for immunoassay development.
The Company's own research is focused on neurological and neurodegenerative conditions and it has discovered and patented blood biomarkers in stroke and brain damage as well as several cancers, solid organ transplant rejection and Alzheimer's disease. Proteome Sciences is based in Cobham, UK with facilities in London and Frankfurt.
|
Proteome Sciences plc |
|
|
www.proteomics.com |
Tel: +44 (0)1932 865065 |
|
Christopher Pearce, Chief Executive Officer |
James Malthouse, Finance Director |
|
Dr. Ian Pike, Chief Business Officer |
|
Public Relations |
|
|
IKON Associates |
Coast Communications |
|
Adrian Shaw |
Matt Baldwin |
|
Tel: +44 (0)1483 535102 |
Tel: +44 (0)1233 503200 |
|
Mobile: +44 (0)797 9900733 |
Mobile: +44 (0)7930 439739 |
|
Email: [email protected] |
Email: [email protected] |
|
Nominated Adviser |
|
Noble & Co |
|
John Llewellyn-Lloyd |
|
Sam Reynolds |
|
Tel: +44 (0)20 7763 2200 |
About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees in 30 countries worldwide. For more information, visit http://www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHERTM
Research. Development. Production.
|
Millipore contact: |
|
For Media: |
|
Karen Marinella Hall |
|
Director of Corporate Communications |
|
(978) 715-1567 |
|
For Investors: |
|
Joshua Young |
|
Director, Investor Relations |
|
(978) 715-1527 |
Related Shares:
Proteome